Processing your request


please wait...

Case Page

 

Case Status:    ONGOING    
On or around 09/24/2019 (Ongoing date of last review)

Filing Date: May 08, 2019

According to the Complaint, Nabriva Therapeutics plc is a biopharmaceutical company that purports to develop novel antiinfective agents to treat serious infections. One of the Company’s product candidates is CONTEPO, an epoxide antibiotic developed by Zavante Therapeutics (“Zavante”), which the Company acquired in July 2018.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the Complaint alleges Defendants failed to disclose to investors: (1) that the Company’s manufacturers failed to meet good manufacturing practices; (2) that these manufacturers would be subject to inspections by the FDA in connection with the Company’s NDA; (3) that, as a result of the manufacturing deficiencies, the Company’s NDA for CONTEPO was unlikely to be approved by the FDA; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

On May 24, 2019, the Court issued an Order consolidating cases. The Court issued an Order appointing Lead Plaintiff and Counsel on July 22. Lead Plaintiff filed a consolidated amended Complaint on September 20. On September 23, Lead Plaintiff corrected the consolidated amended Complaint.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: Ireland

SECURITIES INFORMATION:

Ticker Symbol: NBRV
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: S.D. New York
DOCKET #: 19-CV-04183
JUDGE: Hon. Victor Marrero
DATE FILED: 05/08/2019
CLASS PERIOD START: 11/01/2018
CLASS PERIOD END: 04/30/2019
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Glancy Prongay & Murray LLP (New York)
  2. Law Offices of Howard G. Smith
No Document Title Filing Date
COURT: S.D. New York
DOCKET #: 19-CV-04183
JUDGE: Hon. Victor Marrero
DATE FILED: 09/23/2019
CLASS PERIOD START: 01/04/2019
CLASS PERIOD END: 04/30/2019
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Holzer & Holzer LLC
    1200 Ashwood Parkway, Suite 410, Holzer & Holzer LLC, GA 30338
    770.392.0090 770.392.0029 ·
  2. Pomerantz LLP (Chicago)
    10 South LaSalle Street, Suite 3505 , Pomerantz LLP (Chicago), IL 60603
    312-377-1181 312-377-1184 ·
No Document Title Filing Date
—Related District Court Filings Data is not available